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Abstract 
Background: Many aspects on the correlation between epilepsy and cytokine levels were unclear. This study aims to 
investigate the correlations between cytokine levels and severe epilepsy.
Methods: Totally 1218 epileptic patients were grouped by types of epilepsy: TLE (temporal lobe epilepsy, n = 409), 
XLE (extra-temporal lobe epilepsy, n = 290) and IGE (idiopathic generalized epilepsy, n = 519). Two hundred healthy 
volunteers were as controls. Clinical findings and levels of 14 serum and CSF cytokines and 6 STAT members were col-
lected, measured and analyzed.
Results: Analysis showed no differences in interictal cytokine levels among patients from TLE, XLE and IGE groups. 
Interictal serum levels of IL-1b, IL-1Ra, IL-6, IL-8, IFNγ, IFNλ3 and IL-17a were associated with seizure severity of epileptic 
patients, measured by seizure frequency, VA score or NHS3. Multivariate regression analysis indicated that interictal 
concentrations of serum IL-6, IFNγ, IL-17a, IFNλ3, and CSF IL-6, IL-17a, IFNλ3 were significant biomarkers for patients 
with severe epilepsy. mRNA levels of IL-6, IFNγ, IL-17a, and IFNλ3 were elevated in different types of epilepsy. Activa-
tion of all STATs was elevated in epilepsy, and STAT3 was activated 9-fold in average, which was the highest among all 
STATs.
Conclusions: Interictal serum IL-6, IFNγ, IL-17a, IFNλ3, and CSF IL-6, IL-17a, IFNλ3 could be used as potential biomark-
ers for severe epilepsy. Activation of STATs, especially STAT3, was important in epilepsy. Our findings pointed out 
crucial roles of cytokine levels in epilepsy.
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Background
Cytokines and chemokines are important mediators in 
many physiological and pathological modulations includ-
ing nervous system development, bidirectional signal 
transduction between central and peripheral nerve sys-
tems, cognitive processes, and etc. [1, 2]. Under most 
physiological conditions, cytokine levels are low, but they 
could increase manifold up to hundreds of times their 
basal concentrations in pathological conditions. It has 
been reported that adult brain cells express cytokines 
such as IL-1b, IL-6, IL-8, IL-10, IL-12, IL-15, TNF, CCL2, 
CCL3 and CCL4 [3]. New cytokines are being identified 
in CNS (central nerve system).
Regulations of expression and secretion of cytokines 
and their receptors have been described in patients with 
epilepsy, in addition to animal models of epilepsy [4, 5]. 
For example, serum IL-1b, IL-1Ra, IL-2, IL-4, IL-6, IL-8, 
IFNγ, and IL-17 concentrations were observed to be 
elevated in patients with epilepsy [4–8]. Elevated IL-6 
and IL-17 levels in CSF (cerebrospinal fluid) were also 
reported in publications [8–10]. In addition, both IL-6 
and CCL2 are elevated in the temporal cortex of pedi-
atric patients from families with epilepsy history [11]. A 
recent case–control study indicated that after blocking 
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remission of epileptic symptoms could be achieved [12]. 
Additional reports showed that IL-4, IL-8 and IL-17 con-
centrations may be correlated to seizure frequency and 
severity [7–9, 13]. All above evidences suggest key roles 
of cytokines in diagnosis and treatment of epilepsy. But 
the definite correlations between above cytokines and 
different types of epilepsy, and with seizure severity still 
need to be investigated.
The objective of this study was to analyze the clinical 
and laboratory data of a group of epileptic patients, and 
evaluate the correlations between interictal cytokine 
concentrations and seizure severity in different types of 
epilepsy. This study aims to identify serum markers of 
disease severity in order to facilitate more accurate diag-




Our study population consisted of 1218 interictal patients 
with symptomatic epilepsy who were treated at our insti-
tution from January 2009 to February 2015. Exclusion 
criteria include a history of autoimmune diseases, allergic 
response, immune deficiency disorder, diabetes, psychi-
atric illness, malignancy, severe cognitive impairment, 
or a systemic or central nervous system (CNS) infection 
2 weeks before sample collection. Two hundred age- and 
sex-matched healthy volunteers were involved in this 
study.
Epilepsy was diagnosed by at least two licensed and 
experienced neurologists according to the 2006 Interna-
tional League Against Epilepsy (ILAE) Classification [14]. 
Seizure frequency was evaluated by using seizure diaries 
and seizure severity was by using the National Hospital 
Seizure Severity Scale (NHS3) and the Veterans Admin-
istration Seizures Frequency and Severity Rating Scale 
score (VA score) [15]. TLE (temporal lobe epilepsy), XLE 
(extra-temporal lobe epilepsy) and IGE (idiopathic gener-
alized epilepsy) were diagnosed based on medical history, 
electro-clinical findings (including seizure semiology and 
EEG/video-EEG) and neuro-imaging [10]. A high-resolu-
tion 1.5 Tesla magnetic resonance imaging (MRI) scan of 
the brain with a specific epilepsy protocol was obtained 
to define the etiology, which was classified as normal and 
abnormal.
Data source
All of the interictal parameters included in the investiga-
tion were collected at day 7 from the last seizure attack. 
The collected clinical parameters included demographic 
characteristics (age and sex), clinical parameters (signs 
and symptoms), laboratory values (hematologic, bio-
chemical and microbiological findings), radiologic data, 
epileptic duration, seizure frequency per month in the 
past year, and number of epileptic drugs.
The Harbin Medical University First Hospital Ethics 
Committee approved the study, and all involved healthy 
volunteers and patients gave written informed consent 
for their clinical data and samples (blood, serum and 
CSF) to be used in this study. Human experimentation 
guidelines of PR.China were followed in the conduct of 
this research.
Cytokine level determination
Interictal samples were collected at day 7 from the last 
seizure attack. The plasma was harvested within 30 min 
at 37  °C of venipuncture from EDTA-anticoagulated 
blood samples and stored at −80  °C for subsequent 
cytokine analysis. The concentrations of IL-2, IL-4, IL-6, 
IL-8, IL-10, IFNγ, GM-CSF, TNFα (Bio-Rad, USA), IL-
17a (PeproTech, Rocky Hill, NJ, USA), IL-1β (Bender 
MedSystems, Vienna, Austria), IL1Ra (Cytoscreen, Bio-
source, Belgium), IFNλ1, IFNλ2, IFNλ3, IFNλ4 (eBiosci-
ence, CA, USA), and IL-23 (Invitrogen, Carlsbad, CA, 
USA) were measured by ELISA according to manufac-
turers’ instruction [16–20]. CSF concentrations of IL-6, 
IFNγ, IFNλ3 and IL-17a were measured using human 
cytoline/chemokine MILLIplex kits (Millipore Corp, 
Billerica, MA, USA) [21]. ELISAs were performed in 
duplicate.
Statistical analysis
Averages of numerical variables were presented as 
χ¯ ± SD. Differences were compared by Chi square test for 
categorical data and unpaired Student’s t test for continu-
ous normally distributed data (tested by Wilk-Shapiro 
test). Cytokine concentrations were compared by Mann–
Whitney U test. Correlation between cytokine levels and 
seizure frequency/severity was analyzed by Spearman 
correlation and multivariate linear regression analysis. In 
multivariate regression analysis, variables with a p-value 
less than 0.05 were included in the model, and all of the 
continuous data had skewed distribution and were loga-
rithmically transformed to fit normal distribution. All 
analyses were performed by SPSS software (version 11.0). 
Statistical data in multivariate regression analysis were 




The demographic and clinical data of 1218 patients with 
different types of epilepsy were collected and summa-
rized in Table  1. The average duration of their hospital 
stay was 13.77 ± 11.22 days. All patients were recovered 
and discharged, and no one died. The epileptic patients 
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involved in this study were categorized into three groups 
(TLE (n  =  409), XLE (n  =  290), and IGE (n  =  519)). 
Except for brain MRI, there were no statistic differences 
between groups in term of clinical characteristics (all P 
values >0.05, Table  1). Laboratory findings of epileptic 
patients in each study group were shown in Table 2. No 
significant differences were found between groups (all P 
values >0.05).
Correlation between interictal cytokine levels and different 
types of epilepsy
To discover potential serum biomarkers for differentiate 
TLE, XLE and IGE, we tested 14 interictal cytokine con-
centrations (IL-1b, IL-1Ra, IL-2, IL-4, IL-6, IL-8, IL-10, 
IFNγ, IL-17a, IFNλ1, IFNλ2, IFNλ3, IFNλ4, and IL-23). 
The levels of tested cytokines in patients with different 
types of epilepsy were analyzed. Unfortunately, none of 
these cytokine concentrations showed any statistical sig-
nificance between different epileptic groups (all P > 0.05).
Correlation between interictal serum cytokine levels 
and seizure severity
Next, we tried to investigate whether interictal cytokine 
levels could be used as markers to indicate seizure sever-
ity in patients with different types of epilepsy. Seizure 
frequency, VA score, and NHS3 were used as seizure 
severity scales. Table  3 demonstrated statistical analy-
sis results on each cytokine. If seizure frequency was 
used for seizure severity, then levels of IL-6, IL-8 and 
IL-17a were significant biomarkers in all three types of 
epilepsy. IL-1Ra was for TLE and XLE (P  =  0.041 and 
0.032, respectively), IFNγ, IFNλ2 and IFNλ4 were for 
XLE (P  =  0.008, 0.004 and 0.022), and IFNλ3 for IGE 
(P = 0.003). If VA score was applied, IL-1Ra, IL-6, IFNγ, 
IFNλ3 and IL-17a were severity markers in all types 
of epilepsy. IFNλ2 and IFNλ3 were for TLE (P =  0.042 
and 0.008). IL-1b, IL-8, IFNλ1 and IFNλ3 were for XLE 
(P = 0.033, 0.005, 0.006, and 0.010 respectively). If NHS3 
was used, IL-6, IFNγ and IFNλ3 were good markers in all 
types of epilepsy. IL-1Ra, IL-8 and IL-17a were for TLE 
(P = 0.020, 0.012 and 0.021, respectively), IL-17a and all 
IFNλs were for XLE (P = 0.049, 0.025, 0.049, <0.001 and 
0.006), and IL-1Ra, IL-8, IFNλ1, and IFNλ4 were for IGE 
(P = 0.009, 0.005, 0.011 and 0.043 respectively). Among 
all cytokine concentrations, only IL-6 level was correlated 
to all three severity scaling systems in all three types of 
epilepsy. IFNλ3 was also good for all scaling systems in all 
types of epilepsy, except for frequency in TLE and XLE.
Furthermore, multivariate regression analysis revealed 
that interictal IL-6 concentration was positively related 
to seizure frequency in TLE and IGE (P  =  0.041 and 
0.002, respectively), VA score in IGE (P  <  0.001), and 
NHS3 in XLE (P  =  0.005). IFNγ level was positively 
linked to VA score in XLE (P  =  0.015), and NHS3 in 
TLE (P =  0.023). IL-17a level was positively associated 
with VA score in TLE and IGE (P  =  0.010 and 0.022, 
Table 1 Clinical characteristic of epileptic patients
Refractory epilepsy was defined as >2 seizures/month during last year under 
pharmacologically treatment
VA score Veterans Administration Seizures Frequency and Severity Rating Scale 
score, NHS3 National Hospital Seizure Severity Scale, TLE temporal lobe epilepsy, 
XLE extra-temporal lobe epilepsy, IGE idiopathic generalized epilepsy
Epilepsy syndrome TLE XLE IGE
n 409 290 519
Female/male 90/319 51/239 110/409
Age (mean ± SD, years) 33.2 ± 12.4 31.0 ± 10.9 30.8 ± 10.8
Epilepsy duration (mean ± SD, 
years)
15.1 ± 9.8 19.2 ± 15.2 10.9 ± 11.2
Seizure frequency (mean ± SD, 
seizure/month)
10.0 ± 12.4 19.3 ± 17.3 15.5 ± 11.3
Brain MRI (n, %)
 Normal 316 (77.3) 190(65.5) 519 (100)
 Abnormal 93 (22.7) 100 (34.5) 0
Side of epilepsy (n, %)
 Left 119 (29.1) 78 (26.9) 136 (26.2)
 Right 192 (46.9) 76 (26.2) 166 (32.0)
 Unidentified 98 (24.0) 136 (46.9) 217 (41.8)
Anti-epileptic drugs (n, %)
 None 7 (1.7) 5 (1.7) 7 (1.4)
 Mono-drug 37 (9.0) 39 (13.4) 76 (14.7)
 Poly-drug 365 (89.2) 246 (84.9) 436 (84.0)
 Refractory epilepsy (n, %) 377 (92.2) 268 (92.4) 468 (90.1)
Table 2 Laboratory findings
GLU blood glucose, LYM percentage of lymphocytes, ALT alanine 
aminotransferase, CL blood chlorine, WBC white blood cell counts, CK creatine 
kinase, CK-MB creatine kinase-MB, CRP C-reactive protein, LDH Lactate 
dehydrogenase, TLE temporal lobe epilepsy, XLE extra-temporal lobe epilepsy, 
IGE idiopathic generalized epilepsy
TLE (n = 409) XLE (n = 290) IGE (n = 519)
GLU (mmol/L) 7.3 ± 2.4 6.9 ± 3.3 7.6 ± 4.1
WBC (109/L) 9.3 ± 4.5 10.4 ± 3.2 9.2 ± 4.7
Neutrophils (%) 57.7 ± 21.6 57.1 ± 22.8 60.5 ± 25.7
Lymphocytes (%) 39.6 ± 15.6 37.2 ± 20.5 40.0 ± 16.3
HB (g/dL) 132.2 ± 22.3 118.9 ± 32.1 119.4 ± 33.0
PLT (109/L) 301.2 ± 103.4 290.1 ± 111.1 288.9 ± 143.2
ALT (IU/L) 29.6 ± 25.3 21.2 ± 31.7 27.7 ± 25.7
AST (IU/L) 32.5 ± 26.2 34.9 ± 28.2 31.5 ± 26.5
CK-MB (IU/L) 17.2 ± 28.3 19.3 ± 23.7 17.3 ± 31.1
CRP (mg/L) 3.2 ± 4.2 3.7 ± 4.9 3.3 ± 3.4
LDH (U/L) 254.1 ± 73.2 253.2 ± 76.4 243.6 ± 70.0
K (mmol/L) 4.1 ± 1.3 4.1 ± 1.8 4.3 ± 1.9
Na (mmol/L) 134.8 ± 3.8 135.3 ± 3.3 136.2 ± 4.0
CL (mmol/L) 102.3 ± 39.8 109.2 ± 38.0 101.3 ± 38.3
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respectively). IFNλ3 concentration was positively linked 
to NHS3 in TLE and IGE (P = 0.019 and 0.022), and sei-
zure frequency in IGE (P = 0.034) (Table 4). The overall 
data of statistical analysis on correlations between sei-
zure severity and cytokine levels in TLE, XLE and IGE 
were shown graphically in Fig.  1. If P  <  0.01 was con-
sidered significant, then only IL-6 concentration was 
positively linked to NHS3 in XLE (P  =  0.005), seizure 
frequency and VA score in IGE (P =  0.002 and <0.001, 
respectively).
The mRNA concentrations of 14 tested cytokines 
were evaluated, and the data on IL-6, IL-17a, IFNγ 
and IFNλ3 were shown in Fig.  2, since these four 
cytokines were identified in the multivariate analysis 
(Table 4). The mRNA levels of all these four cytokines 
were correlated to all three types of epilepsy. No dif-
ference was observed between types of epilepsy (all 
P > 0.05).
Correlation between interictal cytokine levels and  
the time to next seizure episodes
Inflammation status may have an impact on the time to 
next seizure episodes, and cytokine levels are known bio-
markers for inflammation intensity. So we analyzed the 
correlation between interictal serum cytokine levels and 
the time (days) to the next seizure episode since the study 
time point. All patients were followed up for 6 months. 
Data were shown in Table 5. IL-6 level was an independ-
ent biomarker for the time to next seizure episode in XLE 
(P = 0.002), IFNγ level was an independent biomarker in 
TLE (P = 0.041), IFNλ3 was in TLE and XLE (P = 0.002 
and 0.032), and IL-17a was in TLE and XLE (P = 0.009 
and <0.001, respectively). If P < 0.01 was considered sta-
tistically significant, then only IFNλ3 and IL-17a levels in 
TLE (P = 0.002 and 0.009, respectively), IL-6 and IL-17a 
in XLE (P =  0.002 and <0.001, respectively) were inde-
pendent biomarkers.
Table 3 Correlation analysis between cytokine levels and disease severity in different types of epilepsy
Freq seizure frequency per month, VA score Veterans Administration Seizures Frequency and Severity Rating Scale score, NHS3 National Hospital Seizure Severity Scale, 
TLE temporal lobe epilepsy, XLE extra-temporal lobe epilepsy, IGE idiopathic generalized epilepsy
* P < 0.05, ** P < 0.01
TLE (n = 409) XLE (n = 290) IGE (n = 519)
Freq VA NHS3 Freq VA NHS3 Freq VA NHS3
IL-1b 0.058 0.098 0.075 0.069 0.033* 0.141 0.069 0.091 0.143
IL-1Ra 0.041* 0.004** 0.020* 0.032* 0.021* 0.078 0.059 0.005** 0.009**
IL-2 0.095 0.121 0.119 0.077 0.089 0.083 0.132 0.244 0.097
IL-4 0.249 0.192 0.104 0.193 0.087 0.102 0.201 0.167 0.131
IL-6 0.002** 0.045* 0.005** 0.003** 0.042* <0.001** 0.001** <0.001** 0.003**
IL-8 0.007** 0.077 0.012* 0.001** 0.005** 0.083 0.031* 0.051 0.005**
IL-10 0.210 0.088 0.089 0.192 0.094 0.078 0.201 0.194 0.076
IFNγ 0.081 0.011* 0.008** 0.008** 0.004** 0.034* 0.066 0.018* 0.010*
IFNλ1 0.091 0.112 0.077 0.004** 0.006** 0.025* 0.092 0.082 0.011*
IFNλ2 0.022* 0.042* 0.121 0.394 0.112 0.049* 0.079 0.099 0.245
IFNλ3 0.101 0.008** <0.001** 0.058 0.010* <0.001** 0.003** 0.045* 0.004**
IFNλ4 0.100 0.192 0.492 0.022* 0.051 0.006** 0.148 0.051 0.043*
IL-17a 0.001** <0.001** 0.021* 0.023* 0.011* 0.049* 0.036* 0.001** 0.078
IL-23 0.172 0.099 0.221 0.255 0.301 0.175 0.141 0.187 0.251
Table 4 Independent biomarkers for severe seizures
Freq seizure frequency per month, VA score Veterans Administration Seizures Frequency and Severity Rating Scale score, NHS3 National Hospital Seizure Severity Scale, 
TLE temporal lobe epilepsy, XLE extra-temporal lobe epilepsy, IGE idiopathic generalized epilepsy
* P < 0.01
TLE (n = 409) XLE (n = 290) IGE (n = 519)
Freq VA NHS3 Freq VA NHS3 Freq VA NHS3
IL-6 0.041 0.005* 0.002* <0.001*
IFNγ 0.023 0.015
IFNλ3 0.019 0.034 0.022
IL-17a 0.010 0.022
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Correlation between interictal CSF cytokine levels 
and seizure severity
To further evaluate the association between cytokine lev-
els and seizure severity, concentrations of CSF IL-6, IFNγ, 
IFNλ3 and IL-17a were tested on 150 patients selected 
from our different epileptic groups, respectively (50 of 
which were with TLE, XLE and IGE, respectively). These 
patients were randomly selected from the 1218 epileptic 
patients in this study, and their demographic and clinical 
features were matched between groups. Statistical analy-
sis demonstrated that CSF IL-6 concentration was an 
independent markers for XLE if NHS3 was used for sei-
zure severity (P = 0.007). CSF IL-17a was an independent 
marker for TLE and IGE if VA score was used (P = 0.039 
and 0.044, respectively). CSF IFNλ3 was an independent 
marker for TLE and NHS3 if NHS3 was used (P = 0.022 
and 0.012, respectively). If P  <  0.01 was considered sta-
tistically significant, then only IL-6 in XLE could be 
recognized as an independent biomarker (Table  6). By 
univariate analysis, CSF IFNγ level was associated with 
TLE if VA or NHS3 (P =  0.045 and 0.033, respectively) 
was applied, but failed to enter the multivariate regres-
sion model.
Activation of STAT family members was elevated 
in epilepsy
STATs are key signaling mediators induced by most inter-
leukins and interferons [22]. The concentrations of acti-
vated all 6 STAT family members were evaluated in blood 
PBMCs of patients with different types of epilepsy. We 
found that activation of all tested STATs was significantly 
elevated in all three types of epilepsy. Among all STAT 
members, STAT3 activation level was increased ninefold 
in average, much higher than other STAT members (3–5 
fold), indicating potential critical role of STAT3 in epi-
lepsy (Fig. 3).
Discussion
Vezzani et al. has well documented that CNS inflamma-
tory processes may play crucial roles in the pathophysi-
ology of seizures and epilepsy [23]. Cytokines are key 
mediators of both pro- and anti-inflammatory processes. 
Previous studies have implicated various cytokines in 
epilepsy [6–8, 24]. Here we tried to investigate the asso-
ciation of interictal concentrations of 10 cytokines to 
seizure severity in three types of epilepsy (TLE, XLE and 
IGE). Our data demonstrated 6 potential biomarkers and 
3 independent biomarkers for severe epilepsy. No signifi-
cant differences were observed among different types of 
epilepsy.
Prior publications have demonstrated the correlation 
between concentrations of certain cytokines and epi-
lepsy. IL-6 is a pleiotropic cytokine expressed in various 
cell types and tissues [25]. Its serum concentration is ele-
vated in the settings of many neurological disorders such 
as Alzheimer’s disease, trauma and meningitis [26–28]. 
Previous publications have indicated elevated IL-6 level 
after focal and generalized seizures in patients with epi-
lepsy [26, 29–32]. In our study, serum interictal IL-6 con-
centration was the only one associated with all seizure 
severity evaluation scales in all three types of epilepsy. In 
multivariate analysis, it was positively linked to severity 
of all three types of epilepsy, indicating that serum IL-6 
may be a good candidate to indicate seizure severity in 
general.
Cytokine levels in CSF are important markers for many 
different diseases [21]. IL-17a is involved in the devel-
opment of many inflammatory diseases and has been 
reported to correlate with disease severity [33]. Another 
report indicated that interictal serum and CSF IL-17a 
concentrations were biomarkers for seizure severity [8], 
which is consistent to our findings. IL-17a is known to 
be able to facilitate migration of active T cells, including 
Th17, across the blood brain barrier [8]. Although, so far, 
there is no unequivocal proof that T cells exacerbate sei-
zures directly, they may possibly play roles in the devel-
opment of seizure indirectly, which could explain why 
IL-17a was significantly elevated in our study. This theory 
requires further investigation to proof.
IFNλs are novel cytokines and their roles in sei-
zures have not been well defined yet. We evaluated the 
serum and CSF level of IFNλs and found that, among 4 
IFNλs, IFNλ3 was associated with seizure severity and 
the time to next seizure episode (Tables  3, 4, 5), which 
Fig. 1 Correlation web of biomarkers and severity indices for three 
types of epilepsies. The cross-correlation of cytokine levels with 
seizure indices for three types of epilepsies was shown in the form of 
directed correlation web. The line thickness indicates the significance 
of the correlations. Bold line The statistical correlation is <0.05 in mul-
tivariate analysis; Thin line The statistical correlation is <0.01 in univari-
ate analysis; Dash line: The statistical correlation is <0.01 in univariate 
analysis. TLE temporal lobe epilepsy, XLE extra-temporal lobe epilepsy, 
and IGE idiopathic generalized epilepsy
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was confirmed by mRNA concentration measurement 
(Fig.  2). This is consistent with previous findings in 
encephalitis [34].
Other cytokines in our study, such as IL-1b, IL-1Ra, 
and IL-8, were also correlated to seizure severity in 
univariate analysis (Table  3). IL-1b concentration was 
reported minimal changed postictally [6]. In our study, 
it was only correlated to VA score in XLE. Publications 
have shown that IL-1Ra level changed dramatically dur-
ing seizure attack [6]. It was linked to seizure sever-
ity in all three types of epilepsy. As a pro-inflammatory 
chemokine, IL-8 has been reported to be involved in 
Fig. 2 Serum mRNA concentration of IL-6, IL-17a, IFNγ and IFNλ3 were elevated in epilepsy. Serum mRNA concentration of IL-6 (a), IL-17a (b), IFNγ 
(c) and IFNλ3 (d) were measured in healthy controls and patients with TLE, XLE or IGE. Data represent a minimum of three independent experi-
ments. Asterisks denote p < 0.05 in comparison to untreated samples. TLE: temporal lobe epilepsy, XLE extra-temporal lobe epilepsy, IGE idiopathic 
generalized epilepsy
Table 5 Correlations between interictal cytokine levels and the time to next seizure episode
TLE temporal lobe epilepsy, XLE extra-temporal lobe epilepsy, IGE idiopathic generalized epilepsy
* P < 0.01
TLE (n = 409) XLE (n = 290) IGE (n = 519)
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
IL-6 0.021 0.101 0.035 0.002* 0.007 0.067
IFNγ 0.002 0.041 <0.001 0.095 0.033 0.121
IFNλ3 0.019 0.002* 0.003 0.032 0.039 0.232
IL-17a 0.011 0.009* 0.002 <0.001* 0.032 0.112
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diseases of respiratory and neurological disorders [35–
37]. In our study, IL-8 level was associated with seizure 
severity of all three types of epilepsy. This is consistent 
with previous publication [7].
Conclusions
Among 14 cytokines, four independent biomarkers (IL-
6, IFNγ, IL-17a and IFNλ3) for severe seizures in three 
different types of epilepsy were identified. All STATs were 
activated in epilepsy, among which, STAT3 was the most 
activated one. Important roles of these cytokines in the 
development of severe seizure could be speculated, and they 
may be used as potential markers to identify severe epilepsy.
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Fig. 3 STATs were activated in patients with different types of epilepsy. PBMCs were extracted from healthy controls and different epileptic patients 
(TLE, XLE and IGE). Levels of activated STAT1 (a), STAT2 (b), STAT3 (c), STAT4 (d), STAT5a (e), and STAT5b (f) were measured by flow cytometry. Data 
represent a minimum of three independent experiments. Asterisks denote p < 0.05 in comparison to untreated samples. TLE temporal lobe epi-
lepsy, XLE extra-temporal lobe epilepsy, IGE idiopathic generalized epilepsy
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IGE: idiopathic generalized epilepsy; NHS3: seizure severity scale 3; VA score: 
veterans administration seizures frequency and severity rating scale score; SD: 
standard deviation.
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